AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel small molecules and biologic therapies intended to change neurodegenerative disease progression. Its lead candidate, ALZT-OP1, employs a multi-modal approach that targets neuroinflammation; the Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled. The company expected trial completion in late 2020 with results anticipated in the first quarter of 2021. After the lead program, AZTherapies is advancing candidates for ALS and post-ischemic stroke cognitive impairment and is pursuing an innovative CAR-Treg program with potential broad application across neurodegenerative diseases. On the financing side, the company recently closed a $33.6M Series C-1 financing and earlier this year received $11.2M from a Series C Preferred Stock financing that raised aggregate gross proceeds of $37.5M. The company is led by Chairman and CEO David R. Elmaleh, Ph.D. AZTherapies' lead candidate is ALZT-OP1, a multi-modal therapy built on targeting neuroinflammation and microglia to slow or stop neurodegeneration. The company has a fully enrolled pivotal Phase 3 trial, COGNITE, being conducted under a Special Protocol Assessment with the U.S. FDA. Proceeds from the recent financing are intended to fund completion of COGNITE and ALZT-OP1 pre-commercial efforts. AZTherapies is also advancing a broader pipeline, including AZT-101, which the company plans to move into a Phase 2 trial for post-ischemic stroke cognitive impairment and a Phase 1/2a trial in ALS. The company is privately held and headquartered in Boston, Massachusetts. Management highlighted the financing will support completing the Phase 3 trial by the end of 2020 and continued pipeline advancement.

Total raised

$60M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2020